PPDT researches and delivers precision diagnostic and treatment services to the field of Prostate Cancer. Revenues have grown from zero to £12m and PPDT, through its partner BXTA, supplies 300+ hospitals in the UK and also is used in 25 countries.

Investcope provided business development support to PPDT, helped it find and negotiate contracts with BXTA, and now supports PPDT with operational support services. Investcope offered PPDT a shared risk/reward fee schedule to align the goals of the two partners.